By packaging lipid nanoparticles with elements that decrease the fibrous nature of solid tumors, researchers can deliver CRISPR therapies in a more efficient manner.
Celine halioua drops into a crouch and greets Bocce, a Chihuahua-dachshund mix with soulful brown eyes, like a long-lost friend. “Oh my God, you’re so beautiful!” she chirps. The two have just met in an upstairs room at Muttville Senior Dog Rescue in San Francisco, where light streams in through the open windows and urine occasionally streams onto the floor. About a dozen elderly dogs, none taller than a kneecap, putter around on the gray linoleum or nap on blankets. When Halioua kneels, her dark hair tumbling over her shoulder, Bocce rests his head blissfully in her lap.
A tragedy of human-canine relations is that a 10-year-old dog such as Bocce is old, while a 28-year-old person such as Halioua is in the prime of life. Bocce is one of the lucky ones. Many dogs can only dream of living as long as he likely will, because dog lifespan is inversely correlated with body size. It’s the opposite of the wider pattern in the animal kingdom, where elephants easily outlast mice, which in turn outlive mosquitoes. A Chihuahua can expect roughly 15 years of life; an Irish wolfhound or Great Dane around seven or eight.
Halioua hopes that the startup whose name is emblazoned on her slim black T-shirt— Loyal —can start to fix this bug in humanity’s 14,000-year-plus wolf bioengineering project. The company, which she founded in 2019 and leads as CEO, is developing drugs to delay aging in dogs and extend their healthy lifespan. She has raised around $58 million and has two drugs in development. In a few years, she hopes to have the first commercial drug—for any species—to state on the label that it delays aging or extends lifespan. That alone would be a triumph, but Halioua sees it as a springboard to a still greater feat: creating similar drugs for humans.
This book explores the psychological impact of advanced forms of artificial intelligence. How will it be to live with a superior intelligence? How will the exposure to highly developed artificial intelligence (AI) systems change human well-being? With a review of recent advancements in brain–computer interfaces, military AI, Explainable AI (XAI) and digital clones as a foundation, the experience of living with a hyperintelligence is discussed from the viewpoint of a clinical psychologist. The theory of universal solicitation is introduced, i.e. the demand character of a technology that wants to be used in all aspects of life. With a focus on human experience, and to a lesser extent on technology, the book is written for a general readership with an interest in psychology, technology and the future of our human condition. With its unique focus on psychological topics, the book offers contributions to a discussion on the future of human life beyond purely technological considerations.
Our cells change over our lifespan and while some of the changes are necessary and beneficial to our body, sometimes they change in a dangerous and life-threatening way.
Knowing what type of cancer mutation you have is one of the best things you can do to narrow down treatment plans and eligibility for clinical trials. A great way to do that is to get Next-Generation Sequencing (NGS) testing done.
An interdisciplinary team of researchers has developed a blueprint for creating algorithms that more effectively incorporate ethical guidelines into artificial intelligence (AI) decision-making programs. The project was focused specifically on technologies in which humans interact with AI programs, such as virtual assistants or “carebots” used in healthcare settings.
“Technologies like carebots are supposed to help ensure the safety and comfort of hospital patients, older adults and other people who require health monitoring or physical assistance,” says Veljko Dubljević, corresponding author of a paper on the work and an associate professor in the Science, Technology & Society program at North Carolina State University. “In practical terms, this means these technologies will be placed in situations where they need to make ethical judgments.”
“For example, let’s say that a carebot is in a setting where two people require medical assistance. One patient is unconscious but requires urgent care, while the second patient is in less urgent need but demands that the carebot treat him first. How does the carebot decide which patient is assisted first? Should the carebot even treat a patient who is unconscious and therefore unable to consent to receiving the treatment?”
At the age of 14, I was diagnosed with a stage 4 hypermutated glioblastoma and a clinical trial saved my life. Now I’m 18 and cancer-free.
Genflow has announced that its adeno-associated virus (AAV) research and development programme in Estonia has received a non-dilutive grant award of €250,000 from the Applied Research Programme of Enterprise Estonia, an Estonian governmental institution designed to stimulate business growth in the country.
Longevity. Technology: Genflow’s research programme is focused on the development of an antiaging gene therapy platform designed to target nearly 100 million patients worldwide who suffer from Werner’s syndrome, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis, an advanced form of NAFLD, as well as other major clinical disorders.
This R&D is a collaborative project between Genflow and IVEX lab OÜ, an Estonian company specialising in the research and development of biotech therapeutics.
Scientists have transplanted human brain cells into the brains of baby rats, where the cells grew and formed connections.
It’s part of an effort to better study human brain development and diseases affecting this most complex of organs, which makes us who we are but has long been shrouded in mystery.
“Many disorders such as autism and schizophrenia are likely uniquely human” but “the human brain certainly has not been very accessible,” said said Dr. Sergiu Pasca, senior author of a study describing the work, published Wednesday in the journal Nature.
The new world-first NHS service should lead to earlier diagnosis and treatment for thousands.
Prior to this, it was assumed that egg cells (oocytes) would contain a complex array of factors needed to reprogram a somatic cell into becoming an embryonic cell. After all, the feat of transforming an aged egg cell and reprogramming it to make a new animal must be controlled by many factors present in the egg cell, or so they thought. Takahashi and Yamanaka turned this idea upside down when they showed that just four of the Yamanaka factors were needed to achieve this transformation.
They used the Yamanaka factors to reprogram adult mouse fibroblasts (connective tissue cells) back to an embryonic state called pluripotency, a state where the cell behaves like an embryonic stem cell and can become any other cell type in the body.
Continue reading “Yamanaka Factors and Partial Cellular Reprogramming” »
